Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study
- PMID: 16365015
- DOI: 10.1158/1055-9965.EPI-05-0602
Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study
Abstract
Epidemiologic evidence of sexual history has emerged as a consistently found risk factor for prostate cancer. Some studies have reported an association between human papillomavirus (HPV) infections and prostate cancer. We did a nested case-control study within cohorts of more than 200,000 men enrolled in three Nordic biobanking projects. Follow-up using cancer registry linkages identified 804 prospectively occurring prostate cancer cases. Four control subjects per case were randomly selected from eligible sets of matched subjects that were alive and free of cancer at the time of diagnosis of the corresponding case and were matched to cases on biobank cohort, age (+/-2 years), county of residence, and date of blood sampling (+/-2 months in the Finnish and Swedish cohorts, +/-6 months in the Norwegian cohort). The serum samples were analyzed by standard ELISAs for the presence of immunoglobulin G antibodies against HPV types 16, 18, and 33. The joint HPV-16/HPV-18/HPV-33 seroprevalence in the joint cohort was 13.4% (107 of 799) among cases and 14.0% (363 of 2,596) among controls (odds ratio, 0.94; 95% confidence interval, 0.74-1.19). There were no noteworthy differences when the data were analyzed by different HPV type, country, or antibody levels. Our data do not support an association between serologic markers of HPV-16, HPV-18, and HPV-33 infections and risk of prostate cancer.
Similar articles
-
Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study.Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):872-5. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14504197
-
Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer.Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):763-8. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12917208
-
A multifaceted study of human papillomavirus and prostate carcinoma.Cancer. 1998 Mar 15;82(6):1118-25. Cancer. 1998. PMID: 9506358
-
Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.Scand J Infect Dis Suppl. 2009;107:3-32. doi: 10.1080/00365540902887730. Scand J Infect Dis Suppl. 2009. PMID: 19408160 Review.
-
Sex and prostate cancer: a new risk factor?Harv Mens Health Watch. 2002 Jan;6(6):7-8. Harv Mens Health Watch. 2002. PMID: 11823170 Review. No abstract available.
Cited by
-
Sexually transmissible infections and prostate cancer risk.Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2374-81. doi: 10.1158/1055-9965.EPI-08-0173. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18768506 Free PMC article. Clinical Trial.
-
Unveiling the Role of Human Papillomavirus in Urogenital Carcinogenesis a Comprehensive Review.Viruses. 2024 Apr 25;16(5):667. doi: 10.3390/v16050667. Viruses. 2024. PMID: 38793549 Free PMC article. Review.
-
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial.Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):614-8. doi: 10.1158/1055-9965.EPI-09-1080. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20142255 Free PMC article.
-
Human papillomavirus 16 or 18 infection and prostate cancer risk: a meta-analysis.Ir J Med Sci. 2011 Jun;180(2):497-503. doi: 10.1007/s11845-011-0692-6. Epub 2011 Mar 12. Ir J Med Sci. 2011. PMID: 21400096
-
Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study.BMC Cancer. 2011 Feb 3;11:53. doi: 10.1186/1471-2407-11-53. BMC Cancer. 2011. PMID: 21291519 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical